In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...